InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $20.650 0.03 (0.15%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,618 Notice of Annual General Meeting/Proxy Form 24 Apr 2026 1:22PM $12.225 $20.650 risen by 68.92%
$2,618 Appendix 4G 24 Apr 2026 1:05PM $12.260 $20.650 risen by 68.43%
$2,618 2025 Annual Report to shareholders 24 Apr 2026 12:58PM $12.140 $20.650 risen by 70.10%
$2,618 Update - Notification of buy-back - NEU 21 Apr 2026 8:56AM $12.480 $20.650 risen by 65.46%
$2,618 Update - Notification of buy-back - NEU 20 Apr 2026 8:32AM $12.490 $20.650 risen by 65.33%
$2,618 Update - Notification of buy-back - NEU 17 Apr 2026 8:48AM $12.480 $20.650 risen by 65.46%
$2,618 Notification of cessation of securities - NEU 10 Apr 2026 4:55PM $12.520 $20.650 risen by 64.94%
$2,618 DAYBUE STIX now broadly available in US for Rett syndrome 8 Apr 2026 9:47AM $12.300 $20.650 risen by 67.89%
$2,618 Notification of cessation of securities - NEU 26 Mar 2026 5:49PM $11.850 $20.650 risen by 74.26%
$2,618 Update - Notification of buy-back - NEU 24 Mar 2026 8:40AM $11.490 $20.650 risen by 79.72%
$2,618 Update - Notification of buy-back - NEU 13 Mar 2026 8:26AM $11.950 $20.650 risen by 72.80%
$2,618 Update - Notification of buy-back - NEU 10 Mar 2026 8:40AM $11.680 $20.650 risen by 76.80%
$2,618 Change of Director's Interest Notice - J Basile 6 Mar 2026 10:25AM $12.590 $20.650 risen by 64.02%
$2,618 Update - Notification of buy-back - NEU 4 Mar 2026 8:42AM $12.560 $20.650 risen by 64.41%
$2,618 Acadia confirms plan to request CHMP re-examination 3 Mar 2026 9:50AM $13.770 $20.650 risen by 49.96%
$2,618 Investor presentation, 27 February 2026 27 Feb 2026 11:54AM $13.480 $20.650 risen by 53.19%
$2,618 2025 royalty income A$65m, profit after tax A$30m 27 Feb 2026 9:59AM $13.440 $20.650 risen by 53.65%
$2,618 Appendix 4E and 2025 full year accounts 27 Feb 2026 9:53AM $13.440 $20.650 risen by 53.65%
$2,618 Acadia reports DAYBUE net sales for 2025 and 2026 guidance 26 Feb 2026 11:15AM $12.710 $20.650 risen by 62.47%
$2,618 Pause in Trading 26 Feb 2026 9:53AM $12.710 $20.650 risen by 62.47%
$2,618 Update - Notification of buy-back - NEU 13 Feb 2026 9:32AM $13.570 $20.650 risen by 52.17%
$2,618 Notification of buy-back - NEU 11 Feb 2026 6:24PM $13.430 $20.650 risen by 53.76%
$2,618 Notification of Neuren investor webinar on 12 February 2026 11 Feb 2026 5:05PM $13.430 $20.650 risen by 53.76%
$2,618 Neuren to commence new on-market share buy-back program 11 Feb 2026 5:00PM $13.430 $20.650 risen by 53.76%
$2,618 First patient dosed in Neuren PMS Phase 3 trial 6 Feb 2026 9:26AM $13.200 $20.650 risen by 56.44%

26 - 50 of 831 results

Page 2 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.